In brief: Cytopia, Visiomed
Wednesday, 27 April, 2005
Cytopia (ASX:CYT) has received ethics approval to begin a Phase I clinical trial of its anti-cancer drug CYT997 at at the Royal Brisbane and Women's Hospital. The trial will be conducted in association with the Queensland Institute of Medical Research and Q-Pharm. Cytopia chief scientific officer Andrew Wilks said that the 30-patient trial would be a non-blinded, dose escalation study in patients with various cancers and could take between nine and twelve months.
Visiomed has received an initial purchase order for approximately 1500 Funhaler asthma spacers from its Australian distributor, Cottman Australia, a subsidiary of Advance Healthcare Group Limited (ASX:AHG). The order will take up 100 per cent of the Visiomed's first production run.
Mouth bacteria linked to increased head and neck cancer risk
More than a dozen bacterial species that live in people's mouths have been linked to a...
Life expectancy gains are slowing, study finds
Life expectancy at birth in the world's longest-living populations has increased by an...
Towards safer epilepsy treatment for pregnant women
New research conducted in organoids is expected to provide pregnant women with epilepsy safer...